Top Markets
#1 DogBull DogBull +36.28%
#2 The Bitcoin Bull The Bitcoin Bull +30.25%
#3 Siacoin Siacoin +27.47%
#4 Merlin's Seal BTC Merlin's Seal BTC +25.80%
#5 Pons Pons +20.43%
#6 MarsCoin MarsCoin +18.55%
#7 Ontology Gas Ontology Gas +18.26%
#8 Cash Cat Cash Cat +17.41%
#9 Akedo Akedo +12.86%
#10 Cryptopia Cryptopia +11.07%
Coin of the day
DogBull DogBull
Settings
Language
ENGLISH
Currency
USD
Theme
VectivBio Holding AG VectivBio Holding AG

VectivBio Holding AG

VECT
Rank in Stocks #14770
VectivBio Holding AG is a clinical-stage biopharmaceutical firm committed to... VectivBio Holding AG is a clinical-stage biopharmaceutical firm committed to identifying, developing, and commercializing treatments for severe rare medical conditions. The company's primary therapeutic focus is apraglutide, a prolonged-acting synthetic peptide analog of glucagon-like peptide-2. This compound is currently in a Phase III clinical trial for individuals with short bowel syndrome-intestinal failure (SBS-IF), and is also being evaluated in a Phase II clinical trial for SBS-IF patients with colon-in-continuity anatomy. Furthermore, apraglutide is undergoing a Phase II clinical study for patients experiencing steroid-refractory gastrointestinal acute graft-versus-host disease (aGvHD). Founded in 2019, VectivBio's corporate headquarters are situated in Basel, Switzerland.
Share Price
$16.85
Last synced: 2023-07-07
Market Cap
$393.50M
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
CH
Trade VectivBio Holding AG (VECT)

Category

Healthcare
P/E ratio for VectivBio Holding AG (VECT)
P/E ratio as of 2026 TTM: 0
According to VectivBio Holding AG latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for VectivBio Holding AG from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 31.44 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 36.85 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 -23.32 -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -17.59 -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.